A novel anti-cancer agent, acetyltanshinone IIA, inhibits oestrogen receptor positive breast cancer cell growth by down-regulating the oestrogen receptor

Cancer Letters

Volumn 346, Issue 1, 2014, Pages 94-103

  Yu, Ting ^a   Zhou, Zhicai ^a   Mu, Yuguang ^b   De Lima Lopes, Gilberto ^c   Luo, Kathy Qian ^a  

^a Nanyang Technological University   (Singapore)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c Johns Hopkins Singapore   (Singapore)

Author keywords

Acetyltanshinone IIA; Anti breast cancer agent; Fulvestrant; Oestrogen receptor; Tamoxifen

Indexed keywords

ACETYLTANSHINONE 2A; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; MESSENGER RNA; NEW DRUG; TAMOXIFEN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG TARGETING; ESR1 GENE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE; GENE TARGETING; GREB1 GENE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; RECEPTOR DOWN REGULATION; TRANSCRIPTION REGULATION;

ACETYLTANSHINONE IIA; ANTI-BREAST CANCER AGENT; FULVESTRANT; OESTROGEN RECEPTOR; TAMOXIFEN;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CHROMATOGRAPHY, LIQUID; DOWN-REGULATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MCF-7 CELLS; PHENANTHRENES; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN;

EID: 84894610439     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.12.023     Document Type: Article

References (43)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2008, 127(2010):2893-2917.
2. Andersen J., Poulsen H.S. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 1989, 64:1901-1908.
3. Slamon D.J., Godolphin W., Jones L.A., Holt J.A., Wong S.G., Keith D.E., Levin W.J., Stuart S.G., Udove J., Ullrich A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
4. Stierer M., Rosen H., Weber R., Hanak H., Spona J., Tuchler H. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann. Surg. 1993, 218:13-21.
5. Nadji M., Gomez-Fernandez C., Ganjei-Azar P., Morales A.R. Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5993 breast cancers. Am. J. Clin. Pathol. 2005, 123:21-27.
6. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 1994, 63:451-486.
7. Picard D., Kumar V., Chambon P., Yamamoto K.R. Signal transduction by steroid hormones: nuclear localization is differentially regulated in estrogen and glucocorticoid receptors. Cell Regul. 1990, 1:291-299.
8. Welshons W.V., Lieberman M.E., Gorski J. Nuclear localization of unoccupied oestrogen receptors. Nature 1984, 307:747-749.
9. King W.J., Greene G.L. Monoclonal antibodies localize oestrogen receptor in the nuclei of target cells. Nature 1984, 307:745-747.
10. Pratt W.B., Toft D.O. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocrinol. Rev. 1997, 18:306-360.
11. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986, 320:134-139.
12. Greene G.L., Gilna P., Waterfield M., Baker A., Hort Y., Shine J. Sequence and expression of human estrogen receptor complementary DNA. Science 1986, 231:1150-1154.
13. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA 1996, 93:5925-5930.
14. Gustafsson J.A. Novel aspects of estrogen action. J. Soc. Gynecol. Investig. 2000, 7:S8-S9.
15. Joab I., Radanyi C., Renoir M., Buchou T., Catelli M.G., Binart N., Mester J., Baulieu E.E. Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones. Nature 1984, 308:850-853.
16. Sullivan W.P., Vroman B.T., Bauer V.J., Puri R.K., Riehl R.M., Pearson G.R., Toft D.O. Isolation of steroid receptor binding protein from chicken oviduct and production of monoclonal antibodies. Biochemistry 1985, 24:4214-4222.
17. Pratt W.B., Sanchez E.R., Bresnick E.H., Meshinchi S., Scherrer L.C., Dalman F.C., Welsh M.J. Interaction of the glucocorticoid receptor with the Mr 90,000 heat shock protein: an evolving model of ligand-mediated receptor transformation and translocation. Cancer Res. 1989, 49:2222s-2229s.
18. Metivier R., Penot G., Hubner M.R., Reid G., Brand H., Kos M., Gannon F. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115:751-763.
19. Reid G., Hubner M.R., Metivier R., Brand H., Denger S., Manu D., Beaudouin J., Ellenberg J., Gannon F. Cyclic, proteasome-mediated turnover of unliganded and liganded ERalpha on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 2003, 11:695-707.
20. Green K.A., Carroll J.S. Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state. Nat. Rev. Cancer 2007, 7:713-722.
21. Hoskins J.M., Carey L.A., McLeod H.L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 2009, 9:576-586.
22. Kansra S., Yamagata S., Sneade L., Foster L., Ben-Jonathan N. Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol. Cell. Endocrinol. 2005, 239:27-36.
23. Clarke R., Leonessa F., Welch J.N., Skaar T.C. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol. Rev. 2001, 53:25-71.
24. Howell A., DeFriend D., Robertson J., Blamey R., Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, 345:29-30.
25. Krell J., Januszewski A., Yan K., Palmieri C. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev. Anticancer Ther. 2011, 11:1641-1652.
26. Tian H.L., Yu T., Xu N.N., Feng C., Zhou L.Y., Luo H.W., Chang D.C., Le X.F., Luo K.Q. A novel compound modified from tanshinone inhibits tumor growth in vivo via activation of the intrinsic apoptotic pathway. Cancer Lett. 2010, 297:18-30.
27. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 2006, 281:9607-9615.
28. Glide, Version 5.0, Schrodinger LLC, New York, in, 2009.
29. Callige M., Kieffer I., Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor alpha by the proteasome. Mol. Cell. Biol. 2005, 25:4349-4358.
30. Lecker S.H., Goldberg A.L., Mitch W.E. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J. Am. Soc. Nephrol. 2006, 17:1807-1819.
31. Tillotson B., Slocum K., Coco J., Whitebread N., Thomas B., West K.A., MacDougall J., Ge J., Ali J.A., Palombella V.J., Normant E., Adams J., Fritz C.C. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo. J. Biol. Chem. 2010, 285:39835-39843.
32. Fiskus W., Ren Y., Mohapatra A., Bali P., Mandawat A., Rao R., Herger B., Yang Y., Atadja P., Wu J., Bhalla K. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin. Cancer. Res. 2007, 13:4882-4890.
33. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocrinol. Rev. 1999, 20:358-417.
34. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997, 138:863-870.
35. Helguero L.A., Faulds M.H., Gustafsson J.A., Haldosen L.A. Estrogen receptors alfa (ERalpha) and beta (ERbeta) differentially regulate proliferation and apoptosis of the normal murine mammary epithelial cell line HC11. Oncogene 2005, 24:6605-6616.
36. Chang E.C., Frasor J., Komm B., Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006, 147:4831-4842.
37. Bagatell R., Khan O., Paine-Murrieta G., Taylor C.W., Akinaga S., Whitesell L. Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer. Clin. Cancer. Res. 2001, 7:2076-2084.
38. Maloney A., Workman P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2:3-24.
39. Gougelet A., Bouclier C., Marsaud V., Maillard S., Mueller S.O., Korach K.S., Renoir J.M. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. J. Steroid Biochem. Mol. Biol. 2005, 94:71-81.
40. Fawell S.E., White R., Hoare S., Sydenham M., Page M., Parker M.G. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. USA 1990, 87:6883-6887.
41. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106(Pt 4):1377-1388.
42. Hoffman R.M. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest. New Drugs 1999, 17:343-359.
43. Hoffman R.M. The multiple uses of fluorescent proteins to visualize cancer in vivo. Nat. Rev. Cancer 2005, 5:796-806.